380. A molecular epidemiological exploration of reduced vancomycin susceptibility in Clostridioides difficile

BACKGROUND: Use of vancomycin to treat Clostridioides difficile infection (CDI) has increased following recent IDSA/SHEA treatment guideline updates, applying a selection pressure for resistance development. We previously demonstrated acquired mutations in VanSR two-component system led to constitut...

Descripción completa

Detalles Bibliográficos
Autores principales: Eubank, Taryn A, Dureja, Chetna, Hurdle, Julian G, Garey, Kevin W, Gonzales-Luna, Anne J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752053/
http://dx.doi.org/10.1093/ofid/ofac492.458

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752053/
http://dx.doi.org/10.1093/ofid/ofac492.458

Ejemplares similares